Research & Development
The discovery of new active compounds is risky, time consuming and costly. With an increasing need for novel antimicrobial solutions due to increased antibiotic resistance, supply is now outstripped by demand and traditional approaches to drug discovery no longer offer a cost-effective way of tackling the problem.
The Syntopix approach identifies new antimicrobial solutions in a cost-effective manner. By focusing on the repositioning of known compounds, or combinations of compounds, with a history of use in humans we uncover previously unknown antimicrobial properties and synergies.
With well-documented pharmacology and toxicity profiles, this approach vastly decreases resource expenditure during R&D, both in terms of time and money. The net result is a more efficient route through discovery, pre-clinical and clinical development which increases the probability of success.
Recent News
23/08/2010 07:00
AGREEMENT WITH GLOBAL CONSUMER PRODUCTS COMPANY
Syntopix signs an exclusive agreement with a world leading health and personal care brands company.
22/06/2010 07:00
Syntopix welcomes a new board member with Mike Townend joining as Non-executive Director
22/04/2009 13:13
03/02/2010 07:00
Syntopix announces a Directorate change with Tom Bannatyne joining as Chairman.
12/11/2009 07:00
Syntopix announces positive results for its lead dermatological compound SYN0126